Oncopeptides’ Pepaxto (melphalan flufenamide) Receives the US FDA’s Approval for Triple Class Refractory Multiple Myeloma

 Oncopeptides’ Pepaxto (melphalan flufenamide) Receives the US FDA’s Approval for Triple Class Refractory Multiple Myeloma

Oncopeptides’ Pepaxto (melphalan flufenamide) Receives the US FDA’s Approval for Triple Class Refractory Multiple Myeloma

Shots:

  • The approval is based on P-II HORIZON study assessing Pepaxto + dexamethasone in 157 patients with r/r MM who have received at least prior 4L of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed mAb
  • The P-II HORIZON study resulted in 23.7 % ORR with 4.2mos. median DoR. Of the subset of 97 patients, 41% had EMD
  • Pepaxto is the first anticancer peptide-drug conjugate approved in multiple myeloma. The company expects Papexto to be commercially available in the US within ~2wks.

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Cowen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post